The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe
Clinical Investigation · 2011
DOI: 10.4155/cli.10.14 ↗At a glance
Journal article in Clinical Investigation, 2011. Written by Finn Akerström and 1 co-authors. 50 references.
Abstract (original language)
Reduction in low-density lipoprotein cholesterol (LDL-C) decreases the burden of coronary artery disease. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) improve cardiovascular disease outcomes by reduction of LDL-C and are currently considered first-line therapy for patients with hypercholesterolemia. Recent evidence has resulted in current guidelines recommending a more aggressive approach, with lower LDL-C goals in high-risk patients. However, despite high doses of statin therapy, targets are not met in all patients. Ezetimibe reduces cholesterol levels, in particular LDL-C, by inhibiting the intestinal absorption of both biliary and dietary cholesterol. When combined with a statin, LDL-C levels are further decreased. Ezetimibe is therefore an attractive adjunct agent to statin therapy when LDL-C targets are not achieved, yet its clinical benefits on cardiovascular outcomes await additional clinical trials. The Improved Reduction of Outcomes: Vytorin Efficacy International Tria...
Cite
APA
Akerström, F., & Rodríguez-Padial, L. (2011). The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. Clinical Investigation. https://doi.org/10.4155/cli.10.14
Vancouver
Akerström F, Rodríguez-Padial L. The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. Clinical Investigation. 2011. doi:10.4155/cli.10.14
BibTeX
@article{Akerstrm2011,
author = {Akerström, Finn and Rodríguez-Padial, Luis},
title = {The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe},
journal = {Clinical Investigation},
year = {2011},
doi = {10.4155/cli.10.14}
}
EUVIMED